These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9067926)

  • 21. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome.
    Jiménez C; Díaz C; Selgas R; Auxiliadora Bajo M; del Peso G; Sánchez-Tomero JA; Gonzalez-Gancedo P
    Adv Perit Dial; 1999; 15():36-9. PubMed ID: 10682069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dialysate cancer antigen 125 in long-term peritoneal dialysis patients.
    Ditsawanon P; Supasyndh O; Aramwit P
    Clin Exp Nephrol; 2014 Feb; 18(1):10-5. PubMed ID: 23757048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dialysate CA125 in stable CAPD patients: no relation with transport parameters.
    Pannekeet MM; Koomen GC; Struijk DG; Krediet RT
    Clin Nephrol; 1995 Oct; 44(4):248-54. PubMed ID: 8575125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors increasing severity of peritonitis in long-term peritoneal dialysis patients.
    Park MS
    Adv Ren Replace Ther; 1998 Jul; 5(3):185-93. PubMed ID: 9686629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients.
    Posthuma N; ter Wee P; Donker AJ; Dekker HA; Oe PL; Verbrugh HA
    Perit Dial Int; 1999; 19(4):334-42. PubMed ID: 10507814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: a possible relationship.
    Carozzi S; Nasini MG; Ravera M; Sanna A; Tirotta A; Lamperi S
    Adv Perit Dial; 1997; 13():7-12. PubMed ID: 9360642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short- and medium-term increase of CA125 in peritoneal effluent using a neutral-pH solution.
    García H; Hernández-Jaras J; Cruz Mdel C; Agramunt I; Calvo C; Cerrillo V
    Perit Dial Int; 2003; 23(4):375-80. PubMed ID: 12968846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients.
    Passadakis P; Panagoutsos S; Thodis E; Tsivara I; Sopassi F; Kartali S; Vargemezis V
    Adv Perit Dial; 1999; 15():40-4. PubMed ID: 10682070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does lymphatic absorption change with the duration of peritoneal dialysis?
    Michels WM; Zweers MM; Smit W; Korevaar J; Struijk DG; van Westrhenen R; Krediet RT
    Perit Dial Int; 2004; 24(4):347-52. PubMed ID: 15335148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dialysate cancer antigen 125 levels in children treated with peritoneal dialysis.
    Bouts AH; Groothoff JW; van Amstel SP; Zweers MM; Davin JC; Krediet RT
    Adv Perit Dial; 2000; 16():328-31. PubMed ID: 11045322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane.
    Moriishi M; Kawanishi H; Watanabe H; Tsuchiya S
    Adv Perit Dial; 2005; 21():21-4. PubMed ID: 16686279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport.
    Rodrigues A; Martins M; Santos MJ; Fonseca I; Oliveira JC; Cabrita A; Melo e Castro J; Krediet RT
    Adv Perit Dial; 2004; 20():8-12. PubMed ID: 15384786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death?
    Cheema H; Bargman JM
    Perit Dial Int; 2013; 33(4):349-52. PubMed ID: 23843586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis.
    Hasuike Y; Moriguchi R; Hata R; Miyagawa K; Kuragano T; Aizawa M; Yamamoto S; Yanase K; Izumi M; Tanimoto T; Nakanishi T
    Am J Nephrol; 2007; 27(6):622-9. PubMed ID: 17851230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morphological studies of mesothelial cells in CAPD effluent and their clinical significance.
    Yamamoto T; Izumotani T; Otoshi T; Kim M
    Am J Kidney Dis; 1998 Dec; 32(6):946-52. PubMed ID: 9856509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Association of Effluent Ca125 with Peritoneal Dialysis Technique Failure.
    Barreto DL; Hoekstra T; Halbesma N; Leegte M; Boeschoten EW; Dekker FW; Krediet RT;
    Perit Dial Int; 2015 Dec; 35(7):683-90. PubMed ID: 26152581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis.
    Dobbie JW
    Perit Dial Int; 1992; 12(1):14-27. PubMed ID: 1347465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis.
    Otsuka Y; Nakayama M; Ikeda M; Sherif AM; Yokoyama K; Yamamoto H; Kawaguchi Y
    Clin Exp Nephrol; 2005 Dec; 9(4):315-319. PubMed ID: 16362159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? A 1-year follow-up study.
    Martikainen T; Ekstrand A; Honkanen E; Teppo AM; Grönhagen-Riska C
    Scand J Urol Nephrol; 2005; 39(5):410-6. PubMed ID: 16257844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Necessity of correcting cancer antigen 125 appearance rates by body surface area.
    Kawanishi H; Moriishi M; Harada Y; Sakikubo E; Nagai T; Tsuchiya S
    Adv Perit Dial; 2000; 16():22-5. PubMed ID: 11045255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.